Media stories about Charles River Laboratories International (NYSE:CRL) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Charles River Laboratories International earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.6241986297762 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Comparing Charles River Laboratories International (CRL) and The Competition (americanbankingnews.com)
- Charles River Laboratories International, Inc. (CRL) Insider Sells $678,150.00 in Stock (americanbankingnews.com)
- Contract Research Organizations (CROs) Services Market is Expected to Rise US$ 40 Billion by 2022 (medgadget.com)
- In Vitro Toxicology Testing Market to Surpass US$ 7,750 Million by 2022 – Persistence Market Research (prnewswire.co.uk)
- Bioburden Testing Market Size will Exceed US$ 907 Million by 2022 (medgadget.com)
Charles River Laboratories International (NYSE:CRL) opened at 109.90 on Monday. The firm has a market capitalization of $5.23 billion, a price-to-earnings ratio of 28.96 and a beta of 0.96. The stock has a 50 day moving average price of $106.75 and a 200-day moving average price of $97.28. Charles River Laboratories International has a one year low of $67.20 and a one year high of $110.59.
Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. During the same period in the previous year, the business earned $1.20 EPS. The business’s quarterly revenue was up 8.1% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International will post $5.10 earnings per share for the current fiscal year.
A number of equities research analysts have commented on CRL shares. Jefferies Group LLC reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, June 14th. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th. Citigroup Inc. reissued a “neutral” rating and issued a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 price objective on the stock in a report on Wednesday, July 12th. Finally, Barclays PLC reissued a “hold” rating and issued a $102.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 19th. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Charles River Laboratories International currently has an average rating of “Buy” and an average target price of $99.59.
TRADEMARK VIOLATION NOTICE: “Charles River Laboratories International (CRL) Earning Somewhat Favorable Press Coverage, Accern Reports” was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://transcriptdaily.com/2017/10/09/charles-river-laboratories-international-crl-earning-somewhat-favorable-press-coverage-accern-reports.html.
In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total transaction of $678,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the sale, the insider now directly owns 11,671 shares of the company’s stock, valued at $783,124.10. The disclosure for this sale can be found here. Insiders sold a total of 22,529 shares of company stock valued at $2,278,496 over the last three months. Company insiders own 2.20% of the company’s stock.
About Charles River Laboratories International
Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.
Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.